Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -76.62 Million SEK | 46.88% |
| 2022 | -58.3 Million SEK | -62.76% |
| 2021 | -35.82 Million SEK | -66.69% |
| 2020 | -21.48 Million SEK | -69.08% |
| 2019 | -12.7 Million SEK | -15.12% |
| 2018 | -11.03 Million SEK | -40.69% |
| 2017 | -7.84 Million SEK | -27.89% |
| 2016 | -6.13 Million SEK | -52.99% |
| 2015 | -4.01 Million SEK | -335.11% |
| 2014 | -921.72 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.18 Million SEK | -75.22% |
| 2024 Q1 | -3.49 Million SEK | 93.18% |
| 2023 Q3 | -6.48 Million SEK | 35.55% |
| 2023 Q4 | -51.26 Million SEK | -690.14% |
| 2023 FY | -30.96 Million SEK | 46.88% |
| 2023 Q1 | -8.7 Million SEK | 51.3% |
| 2023 Q2 | -10.06 Million SEK | -15.69% |
| 2022 Q2 | -15.85 Million SEK | -28.57% |
| 2022 FY | -58.3 Million SEK | -62.76% |
| 2022 Q4 | -17.86 Million SEK | -49.84% |
| 2022 Q3 | -11.92 Million SEK | 24.78% |
| 2022 Q1 | -12.33 Million SEK | 5.47% |
| 2021 Q2 | -8.29 Million SEK | -25.26% |
| 2021 Q1 | -6.62 Million SEK | 14.83% |
| 2021 FY | -35.82 Million SEK | -66.69% |
| 2021 Q4 | -13.04 Million SEK | -66.03% |
| 2021 Q3 | -7.85 Million SEK | 5.29% |
| 2020 FY | -21.48 Million SEK | -69.08% |
| 2020 Q1 | -3.46 Million SEK | 81.59% |
| 2020 Q3 | -3.81 Million SEK | 40.68% |
| 2020 Q4 | -7.77 Million SEK | -103.88% |
| 2020 Q2 | -6.43 Million SEK | -85.36% |
| 2019 Q2 | -2.07 Million SEK | 29.67% |
| 2019 Q1 | -2.94 Million SEK | 31.04% |
| 2019 FY | -12.7 Million SEK | -15.12% |
| 2019 Q3 | 2.03 Million SEK | 198.12% |
| 2019 Q4 | -18.84 Million SEK | -1025.95% |
| 2018 Q3 | -1.97 Million SEK | 20.65% |
| 2018 Q1 | -2.29 Million SEK | -4.05% |
| 2018 Q2 | -2.48 Million SEK | -8.26% |
| 2018 Q4 | -4.27 Million SEK | -116.53% |
| 2018 FY | -11.03 Million SEK | -40.69% |
| 2017 Q2 | -2.2 Million SEK | -14.68% |
| 2017 FY | -7.84 Million SEK | -27.89% |
| 2017 Q4 | -2.2 Million SEK | -46.03% |
| 2017 Q3 | -1.51 Million SEK | 31.32% |
| 2017 Q1 | -1.92 Million SEK | -0.65% |
| 2016 Q1 | -1.51 Million SEK | 3.42% |
| 2016 Q2 | -1.37 Million SEK | 8.92% |
| 2016 FY | -6.13 Million SEK | -52.99% |
| 2016 Q4 | -1.9 Million SEK | -42.75% |
| 2016 Q3 | -1.33 Million SEK | 2.98% |
| 2015 Q3 | -1.1 Million SEK | -15.42% |
| 2015 Q1 | -391 Thousand SEK | -323.08% |
| 2015 Q2 | -953 Thousand SEK | -143.73% |
| 2015 Q4 | -1.56 Million SEK | -42.41% |
| 2015 FY | -4.01 Million SEK | -335.11% |
| 2014 Q3 | -383 Thousand SEK | -38.27% |
| 2014 FY | -921.72 Thousand SEK | 0.0% |
| 2014 Q2 | -277 Thousand SEK | 0.0% |
| 2014 Q4 | 175.27 Thousand SEK | 145.76% |
| 2014 Q1 | -277 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -478.346% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | -100.264% |
| BioGaia AB (publ) | 440.9 Million SEK | 117.379% |
| Enzymatica AB (publ) | -48.06 Million SEK | -59.429% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | -83.147% |
| Gabather AB (publ) | -9.47 Million SEK | -708.792% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -421.969% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | -179.012% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -444.289% |
| ODI Pharma AB | -1.34 Million SEK | -5611.294% |
| Orexo AB (publ) | -109.5 Million SEK | 30.023% |
| Probi AB (publ) | 11.32 Million SEK | 776.899% |
| Swedencare AB (publ) | 173.2 Million SEK | 144.241% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 101.646% |
| Toleranzia AB | -7.89 Million SEK | -871.043% |
| Vivesto AB | -356.71 Million SEK | 78.52% |